Mergers and Acquisitions Recap: BUD Finally BUYS Modelo, Human Genome PUTS OFF Glaxo

Finally, A-B InBev (NYSE:BUD) acquires the outstanding remainder of Grupo Modelo for $20.1 billion, which significantly beats the $12 billion to $15 billion chatter price. Following the reshaping of the beer market, Anthony Bucalo at Santander names Heineken (HINKY.PK) as the biggest loser in the deal, as it is left alone in Mexico’s intense competitive environment. Meanwhile, SABMiller (SBMRY.PK) may now concentrate fully on its own acquisition of Foster’s, since a merger with BUD is no longer a possibility, while the industry gets closer to a full unification.

Don’t Miss: News Corp: We’re Going to Make Like a Banana and SPLIT!

Human Genome (NASDAQ:HGSI) shares jump Friday, as the firm considers the potential for a more robust offer from GlaxoSmithKline (NYSE:GSK). It’s thought at RBC Capital that HGSI might receive a bid of $15 per share, which would significantly exceed the present $13 offer. Once again, GSK extends its tender offer until July 20th, just in case HGSI shareholders change their minds.

Don’t Miss: Here are the TOP Healthcare Sector POPS and DROPS.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.